![Andreas Seidl](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Andreas Seidl
Hoofd Techniek/Wetenschap/O&O bij
FORMYCON AG
Profiel
Andreas Seidl currently works at Formycon AG, as Chief Scientific Officer from 2022.
Dr. Seidl also formerly worked at LEUKOCARE AG, as Chief Operating Officer from 2019 to 2022, Hexal Biotech GmbH, as Head-Analytics & Quality Control from 2002 to 2010, and Novartis AG, as Site Manager from 2010 to 2015.
Dr. Seidl received his doctorate degree from Universität Konstanz.
Actieve functies van Andreas Seidl
| Bedrijven | Functie | Begin |
|---|---|---|
| FORMYCON AG | Hoofd Techniek/Wetenschap/O&O | 01-07-2022 |
Eerdere bekende functies van Andreas Seidl
| Bedrijven | Functie | Einde |
|---|---|---|
LEUKOCARE AG
 LEUKOCARE AG Medical/Nursing ServicesHealth Services Develops protein stabilization and protection solutions | Operationeel Directeur | 01-01-2022 |
| NOVARTIS AG | Corporate Officer/Principal | 01-01-2015 |
Opleiding van Andreas Seidl
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
52
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Universität Konstanz
 Universität Konstanz Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LEUKOCARE AG
LEUKOCARE AG Medical/Nursing ServicesHealth Services Develops protein stabilization and protection solutions | Health Services |
Formycon AG
 Formycon AG Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
